Subscribe
Sign in
Home
Notes
Chat
Pricing
About BPS
Document Library
Sponsored Posts
Free Posts
Archive
Latest
Top
Discussions
ASH Part 2: Anito-cel is off to the races, but will it be fast enough to catch-up to Cilta-cel?
Arcellx presented Phase 2 pivotal iMMagine-1 data for anito-cel, their BCMA-targeted CAR-T for 5L+ relapsed/refractory multiple myeloma (RRMM), at ASH…
Dec 11
•
Big Pharma Sharma
1
Share this post
Big Pharma Sharma
ASH Part 2: Anito-cel is off to the races, but will it be fast enough to catch-up to Cilta-cel?
Copy link
Facebook
Email
Notes
More
ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain
It’s time for the annual ASH meeting, always a showcase for cutting-edge clinical data in competitive areas like blood cancers and hemoglobinopathies.
Dec 9
•
Big Pharma Sharma
1
Share this post
Big Pharma Sharma
ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain
Copy link
Facebook
Email
Notes
More
November 2024
Two things I think coming out of SITC 2024
SITC 2024 brought forward some fascinating data, highlighting both the strides we’re making in immuno-oncology and the hurdles that remain.
Nov 20
•
Big Pharma Sharma
Share this post
Big Pharma Sharma
Two things I think coming out of SITC 2024
Copy link
Facebook
Email
Notes
More
October 2024
Flipping the Script on Failed Immuno-Oncology Targets: The Case for “Inverse-I/O” in Autoimmune Diseases
Since the success of PD-(L)1 therapies, immuno-oncology (I/O) has been a hotbed of activity, with companies scrambling to find the next blockbuster…
Oct 28
•
Big Pharma Sharma
2
Share this post
Big Pharma Sharma
Flipping the Script on Failed Immuno-Oncology Targets: The Case for “Inverse-I/O” in Autoimmune Diseases
Copy link
Facebook
Email
Notes
More
Priority Review Voucher (PRV) Market Update – Big Pharma Unloading its Ammo
Refreshing my PRV tracker database and providing you with the latest analysis of this interesting market
Oct 16
•
Big Pharma Sharma
Share this post
Big Pharma Sharma
Priority Review Voucher (PRV) Market Update – Big Pharma Unloading its Ammo
Copy link
Facebook
Email
Notes
More
TIGIT: Too Legit to Quit? Or Just Can't Hit?
Let's take a look at the controversial TIGIT landscape, what we know, and when we will know whether TIGIT is here to stay or not
Oct 7
•
Big Pharma Sharma
2
Share this post
Big Pharma Sharma
TIGIT: Too Legit to Quit? Or Just Can't Hit?
Copy link
Facebook
Email
Notes
More
1
September 2024
Three Major Implications Coming out of ESMO 2024
Three big strategic implications from three-ish data readouts we saw at ESMO
Sep 20
•
Big Pharma Sharma
Share this post
Big Pharma Sharma
Three Major Implications Coming out of ESMO 2024
Copy link
Facebook
Email
Notes
More
What the Ivonescimab Data at WCLC Tells Us About China's Role in Drug Development
Below I get into my quick thoughts about the ivonescimab HARMONi-2 data and our need to change our view on ex-US/EU data readouts.
Sep 12
•
Big Pharma Sharma
1
Share this post
Big Pharma Sharma
What the Ivonescimab Data at WCLC Tells Us About China's Role in Drug Development
Copy link
Facebook
Email
Notes
More
August 2024
Two charts that highlight the future of GLP-1s after Diabetes and Obesity
I analyze the clinical trial landscape for GLP-1s to paint a picture of how omnipresent GLP-1s may end up being in our lives in the near future
Aug 29
•
Big Pharma Sharma
2
Share this post
Big Pharma Sharma
Two charts that highlight the future of GLP-1s after Diabetes and Obesity
Copy link
Facebook
Email
Notes
More
Rethinking the FDA, Innovation, and the Regulatory State: Parsing Vivek and Balaji’s Vision
An examination of Vivek Ramaswamy's latest conversation with Balaji Srinivasan on the role of the FDA and their vision for dismantling it and the rest…
Aug 19
•
Big Pharma Sharma
2
Share this post
Big Pharma Sharma
Rethinking the FDA, Innovation, and the Regulatory State: Parsing Vivek and Balaji’s Vision
Copy link
Facebook
Email
Notes
More
Why You Should Be Paying Attention to the Emerging IgAN Market
A deep dive into a recent curiosity I had about the IgA Nephropathy (IgAN) market
Aug 6
•
Big Pharma Sharma
Share this post
Big Pharma Sharma
Why You Should Be Paying Attention to the Emerging IgAN Market
Copy link
Facebook
Email
Notes
More
July 2024
ESMO 2024: My Most Interesting Abstracts
Below I’ve summarized the ESMO 2024 abstracts I will be paying close attention to in September (it’s early this year!) and why data from these studies…
Jul 29
•
Big Pharma Sharma
Share this post
Big Pharma Sharma
ESMO 2024: My Most Interesting Abstracts
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
